A Phase 1/2 Randomized, Blinded, Dose-escalation Study to Evaluate the Safety and Efficacy of Intrathecal Administration of AAV9-ABCD1 Gene Therapy (SBT101) in Adult Patients With Adrenomyeloneuropathy
Latest Information Update: 18 Jun 2024
At a glance
- Drugs SBT 101 (Primary)
- Indications Adrenomyeloneuropathy
- Focus Adverse reactions; First in man
- Acronyms PROPEL
- 17 Jun 2024 According to Spur Therapeutics media release, the company Acquired SwanBio Therapeutics ,for Phase 1/2 program for adrenomyeloneuropathy to its clinical-stage pipeline and strengthening CNS expertise also the company plans to report an initial safety update from the higher-dose cohort in this trial in the first half of 2025.
- 04 Oct 2023 According to a SwanBio Therapeutics media release, trial is currently active in the United States and is expanding into Europe following the recent approval of its Clinical Trial Application (CTA) from the Central Committee on Research Involving Human Subjects (CCMO) in the Netherlands.
- 04 Oct 2023 According to a SwanBio Therapeutics media release, Syncona Investment Management Limited, has made an additional $10 million commitment to fund the second cohort of this trial.